Scholars@Duke
Thomas William LeBlanc

Thomas William LeBlanc

Associate Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
Box 2715, DUMC, Durham, NC 27710
2424 Erwin Road, Suite 602, Durham, NC 27705

Scholarly Works - Conferences

Treatment outcomes and unmet needs in patients with acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy (IC): A systematic literature review (SLR).

Conference Journal of Clinical Oncology · June 1, 2026 e18517Background: AML is an aggressive cancer that accounts for around one third of a ... Full text Cite

Longitudinal associations between patient and caregiver quality of life following hematopoietic stem cell transplantation.

Conference Journal of Clinical Oncology · June 1, 2026 12087Background: Caregivers of patients undergoing hematopoietic stem cell transplant ... Full text Cite

Impact of venetoclax dosing on outcomes in AML: A single-center real-world study.

Conference Journal of Clinical Oncology · June 1, 2026 e18511Background: VIALE-A established Aza and Venetoclax (Ven) as first-line therapy ... Full text Cite

Palliative care for AML patients on venetoclax-based therapy: A single-center real-world study

Conference Blood · November 3, 2025 AbstractBackground: Randomized trials demonstrate that patients with AML hospitalized for intensive chemotherapy benefit significantly from ... Full text Cite

Impact of recipient sociodemographic factors on allogeneic transplant conditioning intensity and survival outcomes in myeloid malignancies: A secondary analysis of CIBMTR data

Conference Blood · November 3, 2025 AbstractIntroduction: Sociodemographic factors influence all aspects of the allogeneic hematopoietic cell transplantation (HCT) process. Th ... Full text Cite

Creating a tool for measuring preferences for treating blood cancers in older adults using implementation science

Conference Blood · November 3, 2025 AbstractBackground: Older adults with blood cancers now face complex treatment decisions that require weighing benefits and risks of variou ... Full text Cite

Factors influencing patient treatment selection among bispecific antibodies for relapsed/refractory multiple myeloma (RRMM): A mixed methods study

Conference Blood · November 3, 2025 AbstractBackground Novel immunotherapies such as bispecific antibodies (BsAbs) are rapidly changing the treatment landscape for RRMM, with ... Full text Cite

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Conference Blood · November 3, 2025 AbstractIntroduction: Isocitrate dehydrogenase (IDH) mutations are observed in ~20% of patients with acute myeloid leukemia (AML). In the U ... Full text Cite

Remote multi-vital sign monitoring allows earlier detection of cytokine release syndrome after bispecific T cell engager and chimeric antigen receptor T cell therapies

Conference Blood · November 3, 2025 AbstractIntroduction: Cytokine release syndrome (CRS) is a systemic inflammatory condition seen in 50-80% of patients after bispecific T ce ... Full text Cite

Effectiveness and safety of CPX-351 in younger patients <60 years with newly diagnosed secondary Acute Myeloid Leukemia: Pooled analysis of US (V-RULES) and UK (CREST-UK) real-world studies

Conference Blood · November 3, 2025 AbstractCPX-351 is a therapy approved for newly diagnosed (ND) therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-re ... Full text Cite

A multinational study to explore patient preferences for chronic myeloid leukaemia treatments

Conference Blood · November 3, 2025 AbstractINTRODUCTION: Tyrosine kinase inhibitors (TKIs) enable most patients with chronic phase chronic myeloid leukaemia (CP-CML) to achie ... Full text Cite

Real-world survival outcomes with first-line venetoclax therapy in AML

Conference Blood · November 3, 2025 AbstractIntroduction: Venetoclax, a selective BCL-2 inhibitor combined with a hypomethylating agent (azacitidine or decitabine), has become ... Full text Cite

Transfusion burden among older US patients with relapsed FLT3-mutated Acute Myeloid Leukemia treated with gilteritinib: A Medicare claims-based cohort study

Conference Blood · November 3, 2025 AbstractBackground : Older patients with relapsed acute myeloid leukemia (AML) often require transfusion support due to persistent cytopeni ... Full text Cite

Using Natural Language Processing to Assess Goals-of-Care Conversations for Patients With Cancer.

Conference JCO Clin Cancer Inform · October 2025 PURPOSE: Goals-of-care (GOC) discussions during advanced serious illness and end-of-life (EOL) care are critical. Institutions are increasingly tracking the frequency and timing of GOC documentation, but large-scale content assessments have been limited. W ... Full text Link to item Cite

Abstract P2-01-13: Palliative Care Use and End-of-Life Care Quality in HR+/HER2- Metastatic Breast Cancer

Conference Clinical Cancer Research · June 13, 2025 AbstractBackground: Metastatic breast cancer (MBC) is incurable, but therapeutic advances have improved clinical outcomes for patients with hormone receptor positive (HR+), human epidermal growth factor-2 ne ... Full text Cite

A qualitative analysis of uncertainty in cancer diagnosis and treatment.

Conference Journal of Clinical Oncology · June 2025 e24065Background: Uncertainty is an inherent part of patients’ cancer experiences and can affect their psychological well-bei ... Full text Cite

V-RULES: Real-world effectiveness and safety of CPX-351 in patients with secondary acute myeloid leukemia (AML).

Conference Journal of Clinical Oncology · June 2025 6520Background: CPX-351 was approved for newly diagnosed (ND) therapy-related AML (t-AML) or AML with myelodysplasia-related ... Full text Cite

A digital intervention to enhance engagement with oral oncolytic treatments and assess patient experiences with novel therapies.

Conference Journal of Clinical Oncology · June 2025 11056Background: Adherence to oral oncolytic therapy influences treatment efficacy and outcomes. Effectively managing adheren ... Full text Cite

Real-world patient management practices in responders to venetoclax for newly diagnosed acute myeloid leukemia.

Conference Journal of Clinical Oncology · June 2025 6527Background: Venetoclax (VEN) is approved for adult patients (pts) with newly diagnosed (ND) acute myeloid leukemia (AML) ... Full text Cite

Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort

Conference Blood · November 5, 2024 Background: Hematopoietic Stem Cell Transplantation (HCT) is a life-saving treatment for many patients with hematologic malignancies. Disparities persist across the transplant continuum. ... Full text Cite

Perceptions of Treatment Tolerability and Its Relationship to Income in Patients with Hematologic Malignancy: Findings from the Cancer Experience Registry

Conference Blood · November 5, 2024 Background: Hematologic malignancies (HM) often require therapies associated with a range of bothersome symptoms, side effects, and impacts. Clinical researchers typically consider tolera ... Full text Cite

Treatment Experience of Patients with Acute Myeloid Leukemia in the Era of Novel Therapies: A Longitudinal Electronic Patient-Reported Outcomes Study

Conference Blood · November 5, 2024 Background: Since 2017, novel therapies for acute myeloid leukemia (AML) have emerged as options for patients unfit for high-intensity induction chemotherapy. However, much of our current ... Full text Cite

Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Conference Blood · November 5, 2024 IntroductionFor patients with triple-class exposed multiple myeloma (TCE MM), the prognosis is poor, and limited effective treatment options are availa ... Full text Cite

An Indirect Comparison of Elranatamab's Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Conference Blood · November 5, 2024 BACKGROUNDElranatamab(ELRA) is a BCMAxCD3 bispecific antibody approved for the treatment of relapsed/refractory multiple myeloma (MM) in the United Sta ... Full text Cite

Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Conference Blood · November 5, 2024 Introduction: Chimeric Antigen Receptor (CAR)- T cell therapy has revolutionized the treatment of hematologic malignancies. However, access to CAR-T therapy remains limited, especially fo ... Full text Cite

Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML - a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax

Conference Blood · November 5, 2024 BACKGROUND:Nearly 50% of newly diagnosed (nd) patients with AML are ineligible for intensive chemotherapy (ICi) and are commonly referred to as “unfit” ... Full text Cite

Factors Associated with Early Quality of Life Response to Palliative Care during Hematopoietic Cell Transplantation

Conference Blood · November 5, 2024 Background: Integrated specialty palliative care (PC) during hematopoietic cell transplantation (HCT) improves quality of life (QOL) and reduces physical and psychological symptom burden ... Full text Cite

Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy

Conference Blood · November 5, 2024 Background:Patients with AML and high-risk MDS receiving non-intensive chemotherapy have substantial quality of life (QOL) impairments and often do not ... Full text Cite

Pre-Transplant Patient-Reported Outcomes Are Associated with Health Care Utilization and Transplant-Related Complications at One-Year Post-Transplant

Conference Blood · November 5, 2024 Background: Hematopoietic cell transplantation (HCT) is a potentially curative therapy for patients with many hematologic conditions but is often associated with early- and long-term comp ... Full text Cite

Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Conference Blood · November 5, 2024 IntroductionElranatamab (ELRA) is a BCMAxCD3 bispecific antibody approved for the treatment of relapsed refractory multiple myeloma (RRMM) based on the ... Full text Cite

Experienced or Perceived Burdens and Associated Quality of Life Impacts of Anemia and Transfusion Dependence in Myelofibrosis: A Patient Self-Report Survey Analysis

Conference Blood · November 5, 2024 Background: Myelofibrosis (MF) is associated with debilitating symptoms, which often negatively impact patients' health-related quality of life (QOL) and functioning. While Janus kinase ( ... Full text Cite

The Impact of Multiple Myeloma on Care Partner Well-Being, Work Productivity, and Resource Use in the United States and Western Europe

Conference Blood · November 5, 2024 BACKGROUNDThe impact of multiple myeloma (MM) extends beyond the affected patients themselves as care partners and family members also experience signi ... Full text Cite

Measuring Social Toxicity in Acute Myeloid Leukemia

Conference Blood · November 2, 2023 Background: AML is an aggressive and costly cancer to treat, which often results in lower quality of life, including worse and more frequent depression and anxiety, physical strains, and financial toxicity. AML can also ... Full text Cite

A Comparison of Acute Myeloid Leukemia (AML) Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly Diagnosed Patients with IDH1 Mutations: A Real-World Evidence Study

Conference Blood · November 2, 2023 Background: Two frontline combination regimens are available for patients with mutant IDH1 (mIDH1) AML: ivosidenib (IVO)+hypomethylating agent (HMA), and venetoclax (VEN)+HMA. Robust comparisons between these regimens h ... Full text Cite

An Indirect Comparison of Elranatamab's Progression-Free Survival and Overall Survival from Magnetismm-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Conference Blood · November 2, 2023 BACKGROUNDElranatamab(ELRA) is a BCMAxCD3 bispecific antibody being investigated for the treatment of relapsed/refractory multiple myeloma (MM). The phase 2 MagnetisMM-3 (MM-3; NCT046493 ... Full text Cite

Coping in Patients with Hematologic Malignancies Undergoing Hematopoietic Cell Transplantation

Conference Blood · November 2, 2023 Background Patients undergoing hematopoietic cell transplantation (HCT) must cope with immense physical and psychological symptoms during HCT hospitalization, which contribute to a dramatic deterioration in quality of l ... Full text Cite

Multiple Myeloma Treatment-Related Decision-Making and Preferences of Patients and Care Partners in the United States

Conference Blood · November 2, 2023 BACKGROUNDMultiple myeloma is a largely incurable disease characterized by periods of response followed by relapse and/or refractoriness to therapy. With many new treatments available, p ... Full text Cite

Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Conference Blood · November 2, 2023 Introduction: The BCL-2 inhibitor VEN is approved in combination with hypomethylating agents or low-dose cytarabine for adults with ND AML. The ARC Initiative is a multicenter chart review study of adult pts with AML. T ... Full text Cite

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Conference Blood · November 2, 2023 BACKGROUNDFor patients with triple-class exposed/refractory multiple myeloma (TCE/R MM), prognosis is poor and limited effective treatment options are available. Elranatamab is a novel B ... Full text Cite

Changing Care Journey for Patients with Multiple Myeloma in the United States

Conference Blood · November 2, 2023 BACKGROUNDManagement of the hematologic malignancy multiple myeloma (MM) requires a sequence of treatment decisions across the course of the disease to extend survival and maximize quali ... Full text Cite

Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407)

Conference Blood · November 2, 2023 Background:Patients with hematologic malignancies (HM) receive more aggressive care at the end of life (EOL) and have suboptimal hospice utilization when compared to patients with solid ... Full text Cite

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab and Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Conference Blood · November 2, 2023 BACKGROUNDElranatamab, a novel B-cell maturation antigen (BCMA)- and CD3-directed bispecific antibody, recently demonstrated efficacy and safety in patients with triple-class exposed/ref ... Full text Cite

A Positive Psychology Intervention in Allogeneic Hematopoietic Stem Cell Transplantation Survivors (PATH) to Promote Well-Being: Randomized Controlled Feasibility and Preliminary Efficacy Trial

Conference Blood · November 2, 2023 Background: Patients with hematologic malignancies who are allogeneic hematopoietic stem cell transplantation (HSCT) survivors experience tremendous psychological symptoms (e.g., anxiety and depression symptoms) and low ... Full text Cite

Multi-Site Randomized Trial of Inpatient Palliative Care for Hospitalized Patients Undergoing Hematopoietic Stem Cell Transplantation

Conference Blood · November 2, 2023 Background: Patients with hematologic malignancies experience a substantial decline in their quality of life (QOL) and psychological health during their hospitalization for hematopoietic stem cell transplantation (HSCT) ... Full text Cite

Work absenteeism and disability days after diagnosis among patients with AML and caregivers.

Conference Journal of Clinical Oncology · June 1, 2023 e19002 Background: Treatment for acute myeloid leukemia (AML) includes intensive chemotherapy and/or hematopoietic stem cell transplant, and patients usually require extended hospital stays and absence from work. Caregivers may a ... Full text Cite

Quality for all: Clinical trial enrollment and end-of-life care in solid and hematologic malignancies.

Conference Journal of Clinical Oncology · June 1, 2023 12028 Background: All patients with cancer deserve quality end-of-life (EOL) care.Despite established EOL quality metrics, many patients with cancer receive futile, aggressive EOL care with infrequent palliative care involvement ... Full text Cite

An indirect comparison of elranatamab’s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM).

Conference Journal of Clinical Oncology · June 1, 2023 6618 Background: ELRA is a BCMAxCD3 bispecific antibody being investigated for the treatment of R/R MM. The phase 2 MM-3 trial was single-armed; the aim of this study (NCT05565391) was to contextualize the efficacy data from MM-3 ... Full text Cite

“More than conquerors”: a qualitative analysis of war metaphors for patients with cancer

Conference Supportive Care in Cancer · January 1, 2023 Purpose: Meaning-making is fundamental to the cancer experience and communication within cancer care is saturated with metaphors. The objective of this study was to better understand the impact and function of war metaphors among patients with cancer. Meth ... Full text Cite

Impact of Early Palliative Care on End-of-Life Outcomes in Hematologic Malignancies.

Conference J Palliat Med · April 2022 Background: Patients with hematologic malignancies (HMs) receive more disease directed care at the end of life (EOL) and often die in the hospital. The impact of early palliative care (PC) consultation on EOL quality outcomes in HMs has not been well descr ... Full text Link to item Cite

Palliative care and coping in patients with acute myeloid leukemia: Mediation analysis of data from a randomized clinical trial.

Conference Cancer · December 15, 2021 BACKGROUND: It has been shown previously that integrated palliative care for patients with acute myeloid leukemia (AML) during intensive chemotherapy leads to improvements in quality of life (QOL) and mood. Coping has been shown to mediate palliative care ... Full text Link to item Cite

The Associations between Coping Strategy Use and Patient-Reported Outcomes in Patients with Acute Myeloid Leukemia

Conference Blood · November 5, 2021 AbstractBackground: Patients with acute myeloid leukemia (AML) who receive intensive chemotherapy must cope with immense physical and psychological symptoms associated with a variety of patient-reported outc ... Full text Cite

The Relationship between Depression, Anxiety, and Clinical Trial Perceptions Among Patients with Hematologic Cancer

Conference Blood · November 5, 2021 AbstractIntroduction. Despite the fact that thousands of cancer clinical trials (CCTs) are available today, engagement remains low, with only 2-7% of patients with cancer participating in CCTs. Research has ... Full text Cite

Healthcare Resource Utilization and Costs in US Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Intensive Induction Chemotherapy

Conference Blood · November 5, 2021 AbstractINTRODUCTION:Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy. In the United States (US) in 2020, the incidence of AML was 4.3/100,000, with a d ... Full text Cite

Code Status Transitions in Patients with High-Risk Acute Myeloid Leukemia (AML)

Conference Blood · November 5, 2021 AbstractBackground:Patients with high-risk AML often experience intensive medical care at the end of life (EOL) such as hospitalization and intensive care unit (ICU) admissio ... Full text Cite

Dasatinib Treatment Patterns after Pleural Effusion Among Patients with Chronic Myeloid Leukemia

Conference Blood · November 5, 2021 AbstractIntroductionDecision-making in the treatment (Tx) of chronic myeloid leukemia (CML) is complex and dependent on many factors, including disease phase and drug tolerab ... Full text Cite

What Do Patients Think about Palliative Care? a National Survey of Hematopoietic Stem Cell Transplant Recipients

Conference Blood · November 5, 2021 AbstractBackground: Palliative care (PC) benefits patients with cancer and those undergoing hematopoietic stem cell transplantation (HSCT), but remains under-utilized in HSCT. While transplant physicians hav ... Full text Cite

Acute Myeloid Leukemia in Western Kenya: A Snapshot

Conference Blood · November 5, 2021 AbstractIntroduction: Steady advances in the treatment of acute myeloid leukemia (AML) have improved outcomes in high-resource settings, with a 5-year overall survival rate of 29% and rising in the United St ... Full text Cite

Symptoms and Impacts Reported By Patients with Acute Myeloid Leukemia (AML) in Remission Post-Stem Cell Transplant

Conference Blood · November 5, 2021 AbstractBackgroundLittle is known about the burden of symptoms and impacts on quality of life in patients with AML in the posttransplant period. As treatment options for AML ... Full text Cite

Health-related quality of life in adults with multiple myeloma

Conference QUALITY OF LIFE RESEARCH · October 2021 Link to item Cite

Associations of coping strategies with quality of life (QOL) and mood in patients with acute myeloid leukemia (AML).

Conference Journal of Clinical Oncology · May 20, 2021 e19012 Background: Patients with AML who receive intensive chemotherapy experience immense physical and psychological symptoms, which can result in a substantial deterioration of QOL. As data on the relationship between AML patie ... Full text Cite

Patient concerns and disruptions in cancer care during the COVID-19 pandemic.

Conference Journal of Clinical Oncology · May 20, 2021 e18716 Background: The COVID-19 pandemic has uniquely impacted the lives of people with cancer, but the specifics of these impacts are not fully understood. We examined: 1) the impact of COVID-19 on cancer-related health care, an ... Full text Cite

Code status transitions in patients with high-risk acute myeloid leukemia (AML).

Conference Journal of Clinical Oncology · May 20, 2021 e19009 Background: Patients with high-risk AML often experience aggressive medical care at the end of life (EOL) such as hospitalization and intensive care unit (ICU) admission. Despite this, studies examining code status transit ... Full text Cite

A mixed methods study exploring the role of perceived side effects on treatment decision-making in older adults with acute myeloid leukemia (AML).

Conference Journal of Clinical Oncology · May 20, 2021 7016 Background: AML patients may be treated with intensive chemotherapy (IC), or non-intensive chemotherapy (NIC) or they may receive best supportive care (BSC) or hospice care. Balancing treatment efficacy and toxicities is key ... Full text Cite

Distress in a pandemic: The association of the coronavirus disease-2019 (COVID-19) pandemic with distress and quality of life in hematopoietic stem cell transplantation (HSCT).

Conference Journal of Clinical Oncology · May 20, 2021 7032 Background: The global COVID-19 pandemic has drastically disrupted cancer care, potentially exacerbating patients’ distress levels. Patients with hematologic malignancies undergoing HSCT may be especially vulnerable to this ... Full text Cite

Palliative care and coping in patients with acute myeloid leukemia receiving intensive induction therapy: A mediation analysis of data from a randomized trial.

Conference Journal of Clinical Oncology · May 20, 2021 12007 Background: Patients with acute myeloid leukemia (AML) receiving intensive induction chemotherapy experience significant symptoms, quality of life impairment, anxiety, and depression. We previously showed that integrated pa ... Full text Cite

Systematic review of decision aids in hematologic malignancies

Conference JOURNAL OF THE AMERICAN GERIATRICS SOCIETY · April 2021 Link to item Cite

Treatment Decision-Making and Decisional Support Experiences Among Acute Myeloid Leukemia Survivors

Conference Blood · November 5, 2020 Background: With the availability of newer acute myeloid leukemia (AML) treatment combinations and targeted therapies, it is important for patients to understand all available treatment options, including their associated benefits, risks and side e ... Full text Cite

Decisional Involvement, Information Preferences, and Prognostic Optimism Among Patients with Hematologic Malignancies

Conference Blood · November 5, 2020 Introduction:Understanding decisional involvement and information preferences in patients with hematologic malignancies may help to optimize physician-patient communication about treatment decisions and align the de ... Full text Cite

Financial Burden Is Associated with Postponing Care and Decreasing Physical and Emotional Quality of Life Among Patients with Multiple Myeloma and Chronic Lymphocytic Leukemia

Conference Blood · November 5, 2020 Background: Numerous factors contribute to the financial burden experienced by the cancer population, including medical expenses and possible job disruption or loss. The financial burdens that accompany a cancer diagnosis can influence cancer-care ... Full text Cite

Patient Experiences with Liposomal Daunorubicin and Cytarabine (CPX-351) Versus Conventional Induction Regimens: An Analysis of Patient-Reported Outcomes Data from a Prospective Trial

Conference Blood · November 5, 2020 Background: CPX-351 (Vyxeos®; daunorubicin and cytarabine liposome for injection) is a treatment for adults with newly diagnosed AML with myelodysplasia-related changes or therapy-related AML. Intensive induction chemotherapy causes marked symptom ... Full text Cite

Morphologic Leukemia-Free State in Acute Myeloid Leukemia Is Sufficient for Successful Allogeneic Hematopoietic Stem Cell Transplant

Conference Blood · November 5, 2020 Allogeneic hematopoietic cell transplant (HCT) improves survival in patients with relapsed or high risk acute myeloid leukemia (AML). Complete remission (CR) is typically a pre-requisite for transplantation, though many do not achieve a formal CR. ... Full text Cite

Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML)

Conference Blood · November 5, 2020 Background: Patients with acute myeloid leukemia (AML) receiving intensive chemotherapy face a life-threatening illness, experience a prolonged, isolating hospitalization, and endure substantial physical and psychological symptoms. Some patients wi ... Full text Cite

Annual Healthcare Resource Utilization and Costs in US Patients Diagnosed with Relapsed Acute Myeloid Leukemia

Conference Blood · November 5, 2020 Introduction: Acute myeloid leukemia (AML) is a malignant form of bone marrow cancer commonly diagnosed in older adults. The age-adjusted incidence of AML in the USA is 4.3 per 100,000, with a median age of 68 years at diagnosis. Once diagnosed, tr ... Full text Cite

Multi-Site Randomized Trial of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia (AML)

Conference Blood · November 5, 2020 Background: Patients with AML receiving intensive chemotherapy experience substantial decline in their quality of life (QOL) and mood during their hospitalization for induction chemotherapy and often receive aggressive care at the end of life (EOL) ... Full text Cite

How Do Progression-Free Survival and Toxicity Risks Influence Oncologist and Patient Preferences for Novel Agents in Chronic Lymphocytic Leukemia?

Conference Blood · November 5, 2020 Introduction: Treatment for chronic lymphocytic leukemia (CLL) has changed with the approval of novel agents, which have different toxicity profiles. The aim of the current analysis was to determine how incremental changes in efficacy and toxicity ... Full text Cite

Factors Associated with High Healthcare Utilization at the End-of-Life (EOL) for Patients with Acute Myeloid Leukemia

Conference Blood · November 5, 2020 INTRODUCTION: High rates of healthcare utilization at the EOL have been shown to negatively impact patients' quality-of-life (QOL), psychological distress, and caregivers' bereavement outcomes. Older patients (> 60 years) with acute myeloid ... Full text Cite

Indirect Treatment Comparison of CC-486 Versus Azacitidine (AZA) As Maintenance Therapy for Acute Myeloid Leukemia (AML)

Conference Blood · November 5, 2020 Introduction: For medically fit patients with AML, intensive chemotherapy (IC) is used to induce complete remission (CR). Following CR, some patients may be considered for curative-intent hematopoietic stem cell transplantation. For others, the aim ... Full text Cite

Comparison of End-of-Life Care Quality Outcomes and Indicators of Palliative Needs between Medicare Beneficiaries with Solid and Hematologic Malignancies

Conference Blood · November 5, 2020 Background: Patients (pts) with hematologic malignancies (HM) are thought to have suboptimal hospice utilization and receive more aggressive end of life (EOL) care than those with solid tumors (ST), including high rates of EOL chemotherapy use, ICU ... Full text Cite

Fatigue trajectories in long-term non-Hodgkin lymphoma survivors.

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2020 Link to item Cite

Abstract P5-14-07: Avoidable acute care involving chemotherapy-induced nausea and vomiting (CINV) among patients with breast cancer receiving anthracycline + cyclophosphamide (AC) with NEPA prophylaxis relative to other antiemetics: An external control arm analysis

Conference Cancer Research · February 15, 2020 AbstractBackground: Anthracycline and cyclophosphamide (AC) is a highly emetogenic chemotherapy (HEC) regimen. Combination netupitant/palonosetron (NEPA) + dexamethasone (DEX) is guideline-recommended for pr ... Full text Cite

Billed Palliative Care Services and End-of-Life Care in Patients with Hematologic Malignancies

Conference Blood · November 13, 2019 Background: Patients with hematologic malignancies often receive aggressive care at the end of life (EOL), leading to lower quality of life. Access to early palliative care may improve EOL care outcomes, its benefits are less well established in he ... Full text Cite

Incidence of Invasive Fungal Infections in Acute Leukemia Patients Utilizing Micafungin Prophylaxis Compared to Second-Generation Azole Prophylaxis

Conference Blood · November 13, 2019 Introduction/Background:Standard therapy for both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) is myelosuppressive, and patients are expected to be neutropenic for a prolonged period. Due to t ... Full text Cite

Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family

Conference Blood · November 13, 2019 INTRODUCTION: Acute myeloid leukemia (AML) is a rare hematologic cancer primarily affecting older people, with a median age at diagnosis of 67 years old (Almeida & Ramos, 2016). Heterogeneity in the presentation, functional status and presence ... Full text Cite

Cancer-Related Distress and Unmet Needs Among Acute Myeloid Leukemia Survivors

Conference Blood · November 13, 2019 Background: Individuals with acute myeloid leukemia (AML) are at risk for significant physical and psychological burden related to their illness. While overall survival rates are improving, treatments may be associated with lengthy hospitalizations ... Full text Cite

Oral Adherence in Adults with Acute Myeloid Leukemia: Results of a Mixed Methods Study

Conference Blood · November 13, 2019 BACKGROUND: The incidence of AML is increasing, in part due to the overall aging population; median age at presentation is 67 years. Overall 5-year survival rates are as low as 5%-10% in adults >60 years (Wang, 2014). While standard treatment fo ... Full text Cite

Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma

Conference Blood · November 13, 2019 Background: Peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous group of lymphoid malignancies characterized by a clinically aggressive course with poor prognosis. A majority of PTCL patients are ≥60 years of age and typically present w ... Full text Cite

Understanding Clinician and Patient Preferences about Novel Agents in Chronic Lymphocytic Leukemia

Conference Blood · November 13, 2019 Introduction: Chronic lymphocytic leukemia (CLL) is an indolent disease most common in elderly adults. While chemo-immunotherapy is a standard first-line (1L) therapy for physically fit patients, treatment options for all CLL patients have greatly ... Full text Cite

Oral adherence in adults with acute myeloid leukemia (AML): Results of a mixed methods study.

Conference Journal of Clinical Oncology · November 1, 2019 105 Background: The incidence of AML is increasing, in part due to an aging population. Amid established intravenous (IV) or subcutaneous chemotherapies , recent drug approvals have ushered in an era of oral medication (OM) appro ... Full text Cite

Real-world experience with electronic patient reported outcomes and missing items: "Don't ask me irrelevant questions".

Conference Journal of Clinical Oncology · November 1, 2019 99 Background: Electronic patient-reported outcomes (ePROs) can improve quality of life and prolong survival in patients with cancer by enhancing the detection and tracking of unmet supportive care needs. However, there remain un ... Full text Cite

Acute care and hydration due to chemotherapy-induced nausea and vomiting (CINV) among patients receiving NEPA prophylaxis for anthracycline + cyclophosphamide (AC).

Conference Journal of Clinical Oncology · November 1, 2019 112 Background: In the US, the CMS OP-35 oncology outcome measure deems 30-day post-chemotherapy acute care involving nausea and emesis (NV) or 8 other toxicities as avoidable, with studies showing 15% of > 2500 patients recei ... Full text Cite

Billed palliative care services and end-of-life care in patients with hematologic malignancies.

Conference Journal of Clinical Oncology · November 1, 2019 43 Background: Patients (pts) with hematologic malignancies (HMs) often receive aggressive care at the end of life (EOL), leading to lower quality of life. Early palliative care (PC) may improve EOL care, but its benefits are les ... Full text Cite

Integration of electronic patient-reported outcomes into clinical workflows within the Epic electronic medical record.

Conference Journal of Clinical Oncology · November 1, 2019 102 Background: Electronic patient-reported outcome measures (ePROs) offer a new strategy for symptom assessment that can improve quality of life and prolong survival in routine cancer care. However, ePRO systems are often separa ... Full text Cite

Living with multiple myeloma: A life disrupted.

Conference Journal of Clinical Oncology · November 1, 2019 95 Background: Multiple myeloma (MM) an incurable cancer of the plasma cells is the second most common hematologic malignancy. Over 30,000 new diagnoses and over 12,000 deaths are attributed to MM annually in the United States. D ... Full text Cite

A prototype mobile application to improve communication about symptom management.

Conference Journal of Clinical Oncology · November 1, 2019 27 Background: Cancer patients report many physical and emotional symptoms which can go unreported and underestimated resulting in unmet needs. Research suggests systematic collection of symptom data is associated with decreased ... Full text Cite

Digital Supportive Care Awareness and Navigation (D-SCAN): Results of a pilot randomized trial.

Conference Journal of Clinical Oncology · November 1, 2019 101 Background: Cancer patients face many supportive care needs. In crowded clinics with rising care complexity, clinicians struggle to assess and manage these needs. Duke Cancer Patient Support Program (DCPSP) services aim to br ... Full text Cite

Ondansetron versus palonosetron as a marker of non-adherence to antiemetic prophylaxis guidelines in highly emetogenic chemotherapy.

Conference Journal of Clinical Oncology · May 20, 2019 e23108 Background: ASCO antiemetic guidelines recommend upfront triple prophylaxis (NK1 receptor antagonist (RA) + 5HT3 RA + dexamethasone) for patients receiving highly emetogenic chemotherapy (HEC). Physicians exhibit high vari ... Full text Cite

Abstract P4-16-05: Avoidable acute care use associated with nausea and emesis among patients receiving AC, carboplatin, or cisplatin for breast cancer

Conference Cancer Research · February 15, 2019 AbstractBackground: In order to improve care and reduce costs of cancer treatment, attention has focused on reducing inpatient (IP) and emergency room (ED) utilization. The US Centers for Medicare and Medica ... Full text Cite

Potentially avoidable acute care use among patients receiving oxaliplatin.

Conference Journal of Clinical Oncology · February 1, 2019 651 Background: Oxaliplatin (OX), used primarily in gastrointestinal cancers, is considered moderately emetogenic while multiple guidelines classify carboplatin and cisplatin as highly emetogenic chemotherapy (HEC). The new oncol ... Full text Cite

What do transplant physicians think about palliative care? A national survey study.

Conference Cancer · December 1, 2018 BACKGROUND: Despite its established benefits, palliative care (PC) is rarely utilized for hematopoietic stem cell transplant (HSCT) patients. We sought to examine transplant physicians' perceptions of PC. METHODS: We conducted a cross-sectional survey of t ... Full text Link to item Cite

Quality of life and psychological distress in patients with acute myeloid leukemia (AML).

Conference Journal of Clinical Oncology · December 1, 2018 154 Background: Older patients with AML face difficult treatment decisions as they can be treated either with multi-drug ‘intensive’ chemotherapy requiring a prolonged hospitalization, or ‘non-intensive’ chemotherapy. Although cl ... Full text Cite

Palliative care physicians' beliefs toward hematology and the care of patients with hematologic diseases: Results of a nationwide survey.

Conference Journal of Clinical Oncology · December 1, 2018 95 Background: Palliative care (PC) specialists provide supportive care for patients with hematologic diseases (HD). However, the degree of engagement by PC physicians may be limited by the views of both PC physicians & hemat ... Full text Cite

What the HEC? Physician variation and attainable compliance targets in antiemetic prophylaxis.

Conference Journal of Clinical Oncology · December 1, 2018 74 Background: U.S. National Antiemetic Guidelines recommend upfront triple prophylaxis (NK1 receptor antagonist (RA) + 5HT3 RA + dexamethasone) for patients receiving highly emetogenic chemotherapy (HEC), including carboplatin A ... Full text Cite

Sleep Disturbance Among Individuals with Multiple Myeloma: The Interplay between Physical and Psychosocial Symptoms

Conference Blood · November 29, 2018 AbstractBackground: As long-term survival rates for multiple myeloma (MM) improve, and patients receive more prolonged courses of treatment, individuals living with MM experience cumulative physical symptom ... Full text Cite

Treatment Decision Making and Treatment Satisfaction Among Individuals Living with Chronic Myeloid Leukemia

Conference Blood · November 29, 2018 AbstractBackground: Over the past decade, an increase in treatment options for chronic myeloid leukemia (CML) has dramatically changed the therapeutic landscape and has improved clin ... Full text Cite

End-of-Life Care Quality Outcomes Among Medicare Beneficiaries with Hematologic Malignancies

Conference Blood · November 29, 2018 AbstractBackground: Benefits of hospice care for patients with advanced solid cancers have been extensively studied, but they have not been comprehensively documented in hematologic malignancies (HM). Survey ... Full text Cite

Palliative Care Physicians' Views Toward Hematology and the Care of Patients with Hematologic Diseases: Results of a Nationwide Survey

Conference Blood · November 29, 2018 AbstractBackground: Palliative care specialists provide supportive care for patients with hematologic diseases. However, the degree of engagement by palliative care physicians may b ... Full text Cite

Predictors of Patient-Reported Communication with Their Health Care Team about New Treatment Options for Chronic Lymphocytic Leukemia

Conference Blood · November 29, 2018 AbstractBackground: Chronic lymphocytic leukemia (CLL) progresses with time and, as a result, patients can be challenged by considering multiple treatment options. Importantly, over ... Full text Cite

Psychological distress in myelodysplastic syndromes.

Conference Journal of Clinical Oncology · May 20, 2018 Full text Cite

A National Survey Study of Transplant Physicians' Attitudes About Palliative Care

Conference BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION · March 1, 2018 Link to item Cite

Development of a digital patient navigation application: Preliminary results from patient interviews.

Conference Journal of Clinical Oncology · March 1, 2018 161 Background: People living with cancer face challenges too numerous to attend to during brief clinic visits, and thus may benefit from additional help with supportive care needs. While patient navigators offer promise, they ar ... Full text Cite

Perceptions of unintentional weight loss among cancer survivors.

Conference Journal of Clinical Oncology · March 1, 2018 138 Background: Unintentional weight loss (WL) can be a disruptive symptom of cancer, yet its psychosocial impact is not well understood. We examined cancer survivors’ experiences with unintentional WL. Methods: 320 cancer surviv ... Full text Cite

Patient experiences of acute myeloid leukemia: A qualitative study about diagnosis, illness understanding, and treatment decision-making.

Conference Psychooncology · December 2017 BACKGROUND: Patients with acute myeloid leukemia (AML) face a unique, difficult situation characterized by sudden changes in health, complex information, and pressure to make quick treatment decisions amid sizeable tradeoffs. Yet, little is known about pat ... Full text Link to item Cite

Use of hospice services among Medicare beneficiaries with acute and chronic leukemias.

Conference Journal of Clinical Oncology · November 1, 2017 68 Background: Studies show lower rates of hospice use among patients (pts) with hematologic malignancies. Our objective was to describe trends in hospice use and in quality measures for end-of-life (EOL) care among Medicare bene ... Full text Cite

Open notes: A qualitative study of oncology patients’ experiences reading their cancer care notes.

Conference Journal of Clinical Oncology · November 1, 2017 33 Background: Electronic medical record systems and patient portals increasingly allow patients direct access to their clinicians’ notes.While most believe that open notes benefit patients, some suggest negative consequences. Li ... Full text Cite

Perceptions of prognosis and treatment risk in older patients with acute myeloid leukemia (AML).

Conference Journal of Clinical Oncology · November 1, 2017 43 Background: Older patients ( > 60 years) with AML face difficult treatment decisions as they can be treated either with risky multi-drug “intensive” chemotherapy for a small chance of a cure, or “non-intensive” and non-cura ... Full text Cite

Risk tolerance and attitudes toward chemotherapy: Who chooses palliative treatment when cure is possible?

Conference Journal of Clinical Oncology · May 20, 2017 10054 Background: Many patients with acute myeloid leukemia (AML) face a difficult choice about whether to receive palliative chemotherapy or high-dose, potentially-curative chemotherapy that poses a risk of early death. How peop ... Full text Cite

Patient-reported distress in myelodysplastic syndromes and its relationship with clinical outcomes.

Conference Journal of Clinical Oncology · May 20, 2017 e21564 Background: The National Comprehensive Cancer Network (NCCN) defines distress as an unpleasant emotional experience associated with the psychosocial complications of cancer. Patients with myelodysplastic syndromes (MDS) ar ... Full text Cite

Harmonization of patient-reported outcomes into EHRs at four cancer hospital outpatient clinics for patient care and quality assessment.

Conference Journal of Clinical Oncology · March 10, 2017 129 Background: Patient-reported outcome (PRO) measures are well established in oncology trials but are not collected systematically during clinical care, to guide symptom management, or to assess quality. A growing body of evide ... Full text Cite

Inpatient integrated palliative and transplant care to improve family caregiver (FC) outcomes of patients hospitalized for hematopoietic stem cell transplantation (HCT).

Conference Journal of Clinical Oncology · October 9, 2016 235 Background: As their loved ones struggle physically and psychologically with transplant toxicities, FCs of patients undergoing HCT experience substantial distress. We assessed the impact of an inpatient palliative care interv ... Full text Cite

Sleep quality among inpatients with acute myeloid leukemia.

Conference Journal of Clinical Oncology · October 9, 2016 82 Background: Anecdotally, sleep is thought to be a significant problem for inpatients receiving treatment for acute myeloid leukemia (AML), butsleep disturbances in this setting are not well-characterized. We aimed to assess th ... Full text Cite

Patient-reported distress in adults with myelodysplastic syndromes (MDS).

Conference Journal of Clinical Oncology · October 9, 2016 80 Background: MDS are hematopoietic malignancies that are incurable in most patients. The National Comprehensive Cancer Network (NCCN) defines distress as an unpleasant emotional experience associated with the psychosocial compl ... Full text Cite

Who chooses palliative chemotherapy when a cure is possible? Results of a risk tolerance survey of laypersons.

Conference Journal of Clinical Oncology · October 9, 2016 35 Background: Many patients with acute myeloid leukemia (AML) face a difficult choice about whether to receive palliative chemotherapy or high-dose, potentially-curative chemotherapy that poses a risk of early death. How people ... Full text Cite

Randomized trial of inpatient palliative care in patients hospitalized for hematopoietic stem cell transplantation (HCT).

Conference Journal of Clinical Oncology · October 9, 2016 103 Background: During HCT, patients experience physical and psychological symptoms that negatively impact their quality of life (QOL). We assessed the impact of an inpatient palliative care intervention on patient QOL, symptom b ... Full text Cite

Shared decision-making tools for patients with hematologic malignancies.

Conference Journal of Clinical Oncology · May 20, 2016 Full text Cite

Clinical and Immunomodulatiory Outcomes of Microtransplantation for AML

Conference Biology of Blood and Marrow Transplantation · March 2016 Full text Cite

Multiple Myeloma Patient Experience with Financial Toxicity: Findings from the Cancer Experience Registry

Conference Blood · December 3, 2015 AbstractBackground: The US prevalence of multiple myeloma (MM) is estimated at 83,118 as of January 1, 2011 (SEER, 2014), and about 24,050 new MM cases will be diagnosed in 2014 (ACS, 2014). With advances in ... Full text Cite

Pruritus as an unmet palliative care need in cancer patients: A retrospective cohort study of a Duke patient-reported outcomes database.

Conference Journal of Clinical Oncology · October 10, 2015 97 Background: For cancer patients, the impact of pruritus is not well known, and may be increasing in incidence and severity for those receiving targeted agents. We aimed to describe pruritus in patients with solid tumors, asses ... Full text Cite

Fatigue in long-term non-Hodgkin lymphoma survivors.

Conference Journal of Clinical Oncology · October 10, 2015 239 Background: Fatigue is a common and distressing effect of cancer and its treatment, potentially affecting quality of life (QOL) for years after treatment. However, the prevalence and persistence of fatigue among long-term sur ... Full text Cite

Severity of and contributors to distress in patients with acute myeloid leukemia (AML) receiving induction chemotherapy.

Conference Journal of Clinical Oncology · October 10, 2015 83 Background: Distress screening is a recommended component of comprehensive cancer care, and is now required as a condition of cancer center accreditation by the American College of Surgeons Commission on Cancer. However, the e ... Full text Cite

Symptom burden and palliative care for patients with multiple myeloma: Cancer Experience Registry findings.

Conference Journal of Clinical Oncology · October 10, 2015 81 Background: Multiple myeloma (MM) patients are living longer with treatment advances yet remain challenged by complications and adverse treatment effects. Concurrent oncology/palliative care can improve symptom burden and qual ... Full text Cite

Potentially avoidable hospitalizations in older patients with acute myeloid leukemia (AML).

Conference Journal of Clinical Oncology · October 10, 2015 206 Background: Many older adults ( ≥ 60) with AML have a poor prognosis and spend a significant portion of their life from diagnosis until death in the hospital. We examined the reasons for hospitalizations and identified potent ... Full text Cite

Fatigue in long-term non-Hodgkin lymphoma survivors

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2015 Link to item Cite

Demystifying Nutritional Support in Cancer (FR451)

Conference Journal of Pain and Symptom Management · February 2015 Full text Cite

Palliative Care For Patients With Hematologic Malignancies: A Profile Of Patients With Blood Cancers Referred To The Choice Hospice Network

Conference Blood · November 15, 2013 AbstractBackgroundPublished literature provides an incomplete description of the palliative care needs of the hematologic malignancies ... Full text Cite